Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas

IDH1 mutation can be present in diffuse astrocytomas and giant cell glioblastomas of young children under 10 years of age

(2016) Sean P. Ferris et al.   ACTA NEUROPATHOLOGICA

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Design and synthesis of benzylpiperidine inhibitors targeting the menin–MLL1 interface

(2016) Jing Ren et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Development of New Therapeutic Agents for Fibrodysplasia Ossificans Progressiva.

(2016) Y. Luo et al.   CURRENT MOLECULAR MEDICINE

Recurrent MET fusion genes represent a drug target in pediatric glioblastoma

(2016)   NATURE MEDICINE

Old chemotherapy makes a comeback: dual alkylator therapy for pediatric high-grade glioma

(2016) Eric Bouffet et al.   NEURO-ONCOLOGY

Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study

(2016) Regina I. Jakacki et al.   NEURO-ONCOLOGY

Pediatric high-grade glioma: biologically and clinically in need of new thinking

(2016) Chris Jones et al.   NEURO-ONCOLOGY

Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma

(2016) Hamid Nikbakht et al.   Nature Communications

Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma

(2016) Carl Koschmann et al.   Oncotarget

Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics

(2016) Lindsey M. Hoffman et al.   Acta Neuropathologica Communications

Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma

(2016) Scott Ryall et al.   Acta Neuropathologica Communications

Medulloblastoma subgroups remain stable across primary and metastatic compartments

(2015) Xin Wang et al.   ACTA NEUROPATHOLOGICA

Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes

(2015) David Castel et al.   ACTA NEUROPATHOLOGICA

BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology

(2015) Ganesh M. Shankar et al.   ACTA NEUROPATHOLOGICA

Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations

(2015) David A. Solomon et al.   BRAIN PATHOLOGY

DNA demethylation and invasive cancer: implications for therapeutics

(2015) David Cheishvili et al.   BRITISH JOURNAL OF PHARMACOLOGY

Histone H3 mutations—a special role for H3.3 in tumorigenesis?

(2015) Satish Kallappagoudar et al.   CHROMOSOMA

A preclinical study demonstrating the efficacy of nilotinib in inhibiting the growth of pediatric high-grade glioma

(2015) Karolyn Au et al.   JOURNAL OF NEURO-ONCOLOGY

Functionally defined therapeutic targets in diffuse intrinsic pontine glioma

(2015) Catherine S Grasso et al.   NATURE MEDICINE

Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma

(2015) Melissa M. Singh et al.   NEURO-ONCOLOGY

Isocitrate dehydrogenase mutations in gliomas

(2015) Matthew S. Waitkus et al.   NEURO-ONCOLOGY

Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma

(2015) Pawel Buczkowicz et al.   Frontiers in Oncology

5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft

(2015) Alexandra Borodovsky et al.   Oncotarget

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

(2015) Sevin Turcan et al.   Oncotarget

Epigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors

(2014) Adam M. Fontebasso et al.   ACTA NEUROPATHOLOGICA

Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications

(2014) Pawel Buczkowicz et al.   ACTA NEUROPATHOLOGICA

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

(2014) Giles W Robinson et al.   BMC CANCER

The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma

(2014) Gang Wu et al.   NATURE GENETICS

Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations

(2014) Pawel Buczkowicz et al.   NATURE GENETICS

Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma

(2014) Kathryn R Taylor et al.   NATURE GENETICS

Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma

(2014) Adam M Fontebasso et al.   NATURE GENETICS

An epigenetic therapy for diffuse intrinsic pontine gliomas

(2014) Vijay Ramaswamy et al.   NATURE MEDICINE

Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma

(2014) Rintaro Hashizume et al.   NATURE MEDICINE

For pediatric glioma, leave no histone unturned

(2014) Oren J. Becher et al.   SCIENCE

Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling

(2014) H.-M. Herz et al.   SCIENCE

Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation

(2014) Kosuke Funato et al.   SCIENCE

Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas

(2013) Adam M. Fontebasso et al.   ACTA NEUROPATHOLOGICA

Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma

(2013) Markus Brockmann et al.   CANCER CELL

Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma

(2013) Z. Cheng et al.   CLINICAL CANCER RESEARCH

The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression

(2013) K.-M. Chan et al.   GENES & DEVELOPMENT

A New Class of Small Molecule Inhibitor of BMP Signaling

(2013) Caroline E. Sanvitale et al.   PLoS One

Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma

(2013) P. W. Lewis et al.   SCIENCE

An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

(2013) D. Rohle et al.   SCIENCE

Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

(2013) F. Wang et al.   SCIENCE

Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

(2013) Lynn Bjerke et al.   Cancer Discovery

Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

(2013) Alexandre Puissant et al.   Cancer Discovery

K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas

(2012) Dong-Anh Khuong-Quang et al.   ACTA NEUROPATHOLOGICA

Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma

(2012) Dominik Sturm et al.   CANCER CELL

Distinct Neural Stem Cell Populations Give Rise to Disparate Brain Tumors in Response to N-MYC

(2012) Fredrik J. Swartling et al.   CANCER CELL

AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts

(2012) Radhika Iyer et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts

(2012) G. J. Kitange et al.   CLINICAL CANCER RESEARCH

MEK and RAF inhibitors for BRAF-mutated cancers

(2012) Sarah Belden et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

(2012) Jeremy Schwartzentruber et al.   NATURE

Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia

(2012) Jolanta Grembecka et al.   Nature Chemical Biology

Histone Regulation in the CNS: Basic Principles of Epigenetic Plasticity

(2012) Ian Maze et al.   NEUROPSYCHOPHARMACOLOGY

A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat

(2011) Till Milde et al.   ACTA NEUROPATHOLOGICA

Targeted Therapy for BRAFV600E Malignant Astrocytoma

(2011) T. P. Nicolaides et al.   CLINICAL CANCER RESEARCH

Rapid Radiographic and Clinical Improvement After Treatment of a MET-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor

(2011) Andrew S. Chi et al.   JOURNAL OF CLINICAL ONCOLOGY

Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists

(2011) Kengo Shimono et al.   NATURE MEDICINE

Thalamic high-grade gliomas in children: a distinct clinical subset?

(2011) C. M. Kramm et al.   NEURO-ONCOLOGY

RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma

(2011) K. A. Cole et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Intersegmental vessel formation in zebrafish: requirement for VEGF but not BMP signalling revealed by selective and non-selective BMP antagonists

(2010) JE Cannon et al.   BRITISH JOURNAL OF PHARMACOLOGY

Lestaurtinib Enhances the Antitumor Efficacy of Chemotherapy in Murine Xenograft Models of Neuroblastoma

(2010) R. Iyer et al.   CLINICAL CANCER RESEARCH

MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel

(2010) T. Shimomura et al.   MOLECULAR CANCER THERAPEUTICS

The changing epidemiology of paediatric brain tumours: a review from the Hospital for Sick Children

(2008) Zul Kaderali et al.   CHILDS NERVOUS SYSTEM

EZH1 Mediates Methylation on Histone H3 Lysine 27 and Complements EZH2 in Maintaining Stem Cell Identity and Executing Pluripotency

(2008) Xiaohua Shen et al.   MOLECULAR CELL